SG11202000494UA - Drug delivery composition - Google Patents

Drug delivery composition

Info

Publication number
SG11202000494UA
SG11202000494UA SG11202000494UA SG11202000494UA SG11202000494UA SG 11202000494U A SG11202000494U A SG 11202000494UA SG 11202000494U A SG11202000494U A SG 11202000494UA SG 11202000494U A SG11202000494U A SG 11202000494UA SG 11202000494U A SG11202000494U A SG 11202000494UA
Authority
SG
Singapore
Prior art keywords
international
drug delivery
delivery composition
pct
rue
Prior art date
Application number
SG11202000494UA
Other languages
English (en)
Inventor
Philippe Pouletty
Frédérique Guillamot
Original Assignee
PK Med SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PK Med SAS filed Critical PK Med SAS
Publication of SG11202000494UA publication Critical patent/SG11202000494UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202000494UA 2017-07-25 2018-07-25 Drug delivery composition SG11202000494UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305992 2017-07-25
PCT/EP2018/070141 WO2019020679A1 (fr) 2017-07-25 2018-07-25 Composition d'administration de médicament

Publications (1)

Publication Number Publication Date
SG11202000494UA true SG11202000494UA (en) 2020-02-27

Family

ID=59569251

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000494UA SG11202000494UA (en) 2017-07-25 2018-07-25 Drug delivery composition

Country Status (13)

Country Link
US (1) US20200206354A1 (fr)
EP (1) EP3658114A1 (fr)
JP (2) JP2020528931A (fr)
KR (1) KR20200041886A (fr)
CN (1) CN111093624A (fr)
AU (1) AU2018305161A1 (fr)
BR (1) BR112020001261A2 (fr)
CA (1) CA3069263A1 (fr)
MX (1) MX2020000738A (fr)
RU (1) RU2020107393A (fr)
SG (1) SG11202000494UA (fr)
WO (1) WO2019020679A1 (fr)
ZA (1) ZA202001044B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707556B2 (en) * 2015-01-22 2023-07-25 Alps South, LLC Phase change material for thermal therapy and delivery of active ingredients
EP3658117A1 (fr) 2017-07-25 2020-06-03 Pk Med Sas Procédé de préparation d'une composition d'administration de médicament
AU2020245092A1 (en) 2019-03-28 2021-10-14 Pk Med Multicomponent thermoplastic product
GB202005073D0 (en) 2020-04-06 2020-05-20 Mellizyme Biotechnology Ltd Enzymatic degradation of plastics
WO2022093784A1 (fr) * 2020-10-29 2022-05-05 Alps South, LLC Matériau à changement de phase pour thérapie thermique et administration de principes actifs
WO2023016848A1 (fr) * 2021-08-09 2023-02-16 Basf Se Poudre de frittage (sp) comprenant au moins un polylactide et au moins un polycaprolactone
FR3144996A1 (fr) * 2023-01-18 2024-07-19 Carbiolice Melange maitre enzyme comprenant des proteines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5163952A (en) * 1990-09-14 1992-11-17 Michael Froix Expandable polymeric stent with memory and delivery apparatus and method
WO1998022093A1 (fr) * 1996-11-19 1998-05-28 Octoplus B.V. Procede de preparation d'un systeme a liberation retardee
US8828419B2 (en) * 2006-10-06 2014-09-09 Cordis Corporation Bioabsorbable device having encapsulated additives for accelerating degradation
US8404469B2 (en) * 2007-08-07 2013-03-26 Polytechnic Institute Of New York University Embedded enzymes in polymers to regulate their degradation rate
JP5497653B2 (ja) * 2007-11-14 2014-05-21 エムアー．イ．アー ワウンドケアー 成分の制御送達のための生体材料
US9474715B2 (en) * 2011-11-30 2016-10-25 Andreas Voigt Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition
FR2984354A1 (fr) * 2011-12-20 2013-06-21 Centre Nat Rech Scient Procede de preparation d'alliage polymere/enzymes
DE102015209608A1 (de) * 2015-05-26 2016-12-01 Volkswagen Aktiengesellschaft Torsionsschwingungsdämpfer sowie eine mit einem solchen Torsionsschwingungsdämpfer ausgestattete Brennkraftmaschine
US10723848B2 (en) * 2015-06-12 2020-07-28 Carbios Masterbatch composition comprising a high concentration of biological entities

Also Published As

Publication number Publication date
CN111093624A (zh) 2020-05-01
KR20200041886A (ko) 2020-04-22
EP3658114A1 (fr) 2020-06-03
AU2018305161A1 (en) 2020-01-30
MX2020000738A (es) 2020-08-17
JP2023159157A (ja) 2023-10-31
US20200206354A1 (en) 2020-07-02
BR112020001261A2 (pt) 2020-07-21
CA3069263A1 (fr) 2019-01-31
JP2020528931A (ja) 2020-10-01
RU2020107393A3 (fr) 2021-10-25
RU2020107393A (ru) 2021-08-25
WO2019020679A1 (fr) 2019-01-31
ZA202001044B (en) 2022-10-26

Similar Documents

Publication Publication Date Title
SG11202000494UA (en) Drug delivery composition
SG11201909949XA (en) Targeted immunotolerance
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201907846VA (en) Therapeutic rna
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201903167QA (en) Compounds and methods for reducing atxn3 expression
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201901558VA (en) Pth compounds with low peak-to-trough ratios
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201805001UA (en) Method of treating influenza a
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201806267QA (en) Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose
SG11201809534UA (en) Methods of treating autoimmune disease using allogeneic t cells
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201903795WA (en) Salts of indazole derivative and crystals thereof
SG11201908393YA (en) Modulators of pcsk9 expression
SG11201906313SA (en) A polypeptide linker for preparing multispecific antibodies